Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Eton Pharmaceuticals, Inc. (ETON : NSDQ)
 
 • Company Description   
Eton Pharmaceuticals Inc. operates as a development stage biotechnology company. Its product pipeline consists of DS-300, EM-100, DS-100, DS-200, ET-103, ET-101, ET-102 and CT-100 which are in clinical stage. Eton Pharmaceuticals Inc. is based in Deer Park, Illinois.

Number of Employees: 44

 
 • Price / Volume Information   
Yesterday's Closing Price: $32.59 Daily Weekly Monthly
20 Day Moving Average: 421,508 shares
Shares Outstanding: 27.39 (millions)
Market Capitalization: $892.71 (millions)
Beta: 0.82
52 Week High: $35.66
52 Week Low: $13.09
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 41.88% 34.95%
12 Week 88.93% 74.65%
Year To Date 92.73% 90.29%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
21925 W. FIELD PARKWAY SUITE 235
-
DEER PARK,IL 60010
USA		 ph: 847-787-7361
fax: -		 investorrelations@etonpharma.com http://www.etonpharma.com
 
 • General Corporate Information   
Officers
Sean E. Brynjelsen - Chief Executive Officer;President and Director
James Gruber - Chief Financial Officer; Treasurer and Secretary
Jennifer M. Adams - Director
Charles J. Casamento - Director
Paul V. Maier - Director

Peer Information
Eton Pharmaceuticals, Inc. (CORR.)
Eton Pharmaceuticals, Inc. (RSPI)
Eton Pharmaceuticals, Inc. (CGXP)
Eton Pharmaceuticals, Inc. (BGEN)
Eton Pharmaceuticals, Inc. (GTBP)
Eton Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 29772L108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/06/26
Share - Related Items
Shares Outstanding: 27.39
Most Recent Split Date: (:1)
Beta: 0.82
Market Capitalization: $892.71 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.15 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.82 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/06/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 39.50
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 29.16
Price/Cash Flow: 6,287.62
Price / Sales: 10.27
EPS Growth
vs. Year Ago Period: -28.57%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: 40.41%
vs. Previous Quarter: 14.03%
ROE
03/31/26 - -5.68
12/31/25 - -2.60
09/30/25 - -11.32
ROA
03/31/26 - -1.49
12/31/25 - -0.66
09/30/25 - -2.96
Current Ratio
03/31/26 - 1.21
12/31/25 - 1.57
09/30/25 - 1.63
Quick Ratio
03/31/26 - 0.88
12/31/25 - 1.17
09/30/25 - 1.25
Operating Margin
03/31/26 - -1.70
12/31/25 - -0.79
09/30/25 - -3.86
Net Margin
03/31/26 - -1.70
12/31/25 - -5.75
09/30/25 - -9.50
Pre-Tax Margin
03/31/26 - -1.71
12/31/25 - -5.70
09/30/25 - -9.22
Book Value
03/31/26 - 1.12
12/31/25 - 0.98
09/30/25 - 0.86
Inventory Turnover
03/31/26 - 2.23
12/31/25 - 2.14
09/30/25 - 1.97
Debt-to-Equity
03/31/26 - 0.62
12/31/25 - 0.83
09/30/25 - 1.19
Debt-to-Capital
03/31/26 - 38.22
12/31/25 - 45.42
09/30/25 - 54.40
 

Powered by Zacks Investment Research ©